plusbiome AG

Plusbiome is validating pathways between the gut microbiome and the immune system. Our therapeutic ambition is to regulate selectively these mechanisms to drive effective anti-cancer immunity. We do this with interventions that mimic small and large molecules involved in the microbiome-immune pathways. We develop own asset plus001 in-house, other complementary assets and associated IP will be in-licensed from US research groups. Changing lives of cancer patients and their families for the better.